Recent News

10-07-25 – ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025

09-29-25 – ImmuCell Announces Selection of its Next President and CEO

08-14-25 – ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025

08-12-25 – ImmuCell Announces Bank Debt Refinancing

08-07-25 – ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025

07-09-25 – ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025

06-25-25 – ImmuCell Embarks on CEO Succession Planning Process

06-05-25 – ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

05-14-25 – ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025

05-12-25 – ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025

04-08-25 – ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025

04-07-25 – ImmuCell Hires Chief Financial Officer

04-02-25 – ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®

02-25-25 – ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024

02-20-25 – ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024

01-16-25 – ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses

01-09-25 – ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024